Press release from PR Newswire
Questcor to Report Fourth Quarter and Full Year 2010 Earnings and Conduct Conference Call on February 23, 2011
Monday, February 07, 2011
Questcor to Report Fourth Quarter and Full Year 2010 Earnings and Conduct Conference Call on February 23, 201106:30 EST Monday, February 07, 2011ANAHEIM, Calif., Feb. 7, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it will release financial results for the fourth quarter and full year ended December 31, 2010 on Wednesday, February 23, 2011 after the close of the U.S. financial markets. The Company will host a conference call and webcast on Wednesday, February 23, 2011 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the fourth quarter and full year 2010, as well as current corporate developments. This date is a schedule change from the Company's previously announced expectation to report fourth quarter and year-end results on February 22, 2011 announced in the January 10, 2011 press release. Conference call details:Date:Wednesday, February 23, 2011Time:4:30 p.m. ETDial-in (U.S.):877-941-6010Dial-in (International):480-629-9772Web cast:www.questcor.comTo access an audio replay of the call:Replay (U.S.):800-406-7325Replay (International):303-590-3030Replay Passcode:4408313About Questcor Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose products help patients with serious, difficult-to-treat medical conditions. Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from two indications: the treatment of acute exacerbations of multiple sclerosis in adults and the treatment of infantile spasms in children under two years of age. Questcor is also implementing plans to commercialize Acthar for use in treating nephrotic syndrome, another on-label indication. Specifically with respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor also markets Doral® (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com. SOURCE Questcor Pharmaceuticals, Inc.For further information: Don Bailey of Questcor Pharmaceuticals, Inc., +1-510-400-0776, dbailey@Questcor.com; or Investors, Gregory Gin or Doug Sherk, +1-415-896-6820, or Media, Janine McCargo, +1-646-688-0425, all of EVC Group for Questcor Pharmaceuticals, Inc.